Recently, several studies reported that the use of methyltransferase inhibitor decitabine (DAC) could reverse the expression of GSDME and, thus, improve the sensitivity of tumor cells to chemotherapeutic drugs (doxorubicin and cisplatin), providing new insights into the mechanism of chemotherapeutic drug resistance [14,15]. This evidence concerns the gene GSDME and neoplasm.